GSK, asthma and Depemokimab

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...
GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other cheapest stocks with biggest upside potential. Stocks rallied on January 15, following an encouraging ...
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.
Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...